LivaNova appoints J. Christopher Barry to Board; Andrea Saia to retire Dec 31

LivaNova PLC

J. Christopher Barry appointed to Board and Audit and Compliance Committee, effective Oct 6, 2023.
Barry is former CEO of NuVasive (until merger with Globus Medical in Sept 2023) and ex-SVP at Medtronic.
Barry will receive annual retainer of $110k, audit committee fee $15k, and $130k restricted stock award.
Andrea Saia notified retirement from Board effective Dec 31, 2023; no disagreement cited.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

J. Christopher Barry

Director

LIVN · LivaNova PLC

Effective: 2023-10-06
Filed: October 6, 2023, 7:59 PM ET

appointed J. Christopher Barry to the Board and as a member of the Audit and Compliance Committee of the Board.

Departed

Andrea Saia

Director

LIVN · LivaNova PLC

Effective: 2023-12-31
Filed: October 6, 2023, 7:59 PM ET

Andrea Saia notified the Company of her decision to retire from the Board, effective December 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

J. Christopher Barry was appointed as Director at LivaNova PLC.

Action: appointed
Role: Director

Exact text from the filing

appointed J. Christopher Barry to the Board and as a member of the Audit and Compliance Committee of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrea Saia retired as Director at LivaNova PLC.

Action: retired
Role: Director

Exact text from the filing

Andrea Saia notified the Company of her decision to retire from the Board, effective December 31, 2023.

View on SEC.gov

LivaNova PLC filing history →

Source: SEC EDGAR

accession 0001639691-23-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.